Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Viruses of the Parvoviridae family constitute a most diverse and intriguing field of research. Parvoviruses can differ widely in their structure, genome organization and expression, virus–cell interactions, and impact on hosts. The translational implication of research on parvoviruses is relevant, since many viruses are important human and veterinary pathogens, while other viruses can be engineered as tools for oncolytic therapy or as sophisticated gene delivery vectors. Exploring the diversity and inherent complexity in the biology of these apparently simple viruses is a still challenging topic for the scientific community. The Special Issue of Viruses is a collection of recent contributions in the field of parvovirus research, encompassing many aspects of basic and translational research on viruses of the family Parvoviridae, including on their structure, replication, and gene expression in addition to virus–host interactions and the development of vaccines and viral vectors.

Public health & preventive medicine --- feline parvovirus --- virus-like particles --- VP2 protein --- antibodies --- AAV --- neuro-degenerative disease --- gene therapy --- antigenicity --- sequencing --- virus --- canine parvovirus --- peri-urban --- wild dogs --- disease transmission --- Australia --- parvovirus B19 --- G-quadruplex --- bioinformatics --- antivirals --- BRACO-19 --- pyridostatin --- oncolytic viruses --- rodent protoparvovirus H-1PV --- virus entry --- clathrin-mediated endocytosis --- parvovirus --- minute virus of mice --- RNA processing --- gene expression --- canine --- COVID-19 --- veterinary epidemiology --- B19V --- VP1u --- receptor --- PLA2 --- erythroid cells --- biomarker --- drug delivery --- nanocarrier --- B19 parvovirus --- detection --- cell cycle --- permissivity --- serotype --- capsid --- cryo-EM --- genome packaging --- gene delivery --- bocavirus --- Caribbean region --- new CPV-2a --- outbreak --- endemic --- nearly complete genomes --- virus evolution --- parvoviruses --- nucleus --- imaging of viral interactions and dynamics --- analysis of protein–protein interactions --- analysis of virus–chromatin interactions --- AMDV --- Aleutian disease --- mink parvovirus --- Aleutian mink disease virus --- vaccine

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Viruses exhibit an elegant simplicity as they are so basic, but so frightening. Although only a few are life threatening, they have substantial implications for human health and the economy, as exemplified by the ongoing coronavirus pandemic. Viruses are rather small infectious agents found in all types of life forms, from animals and plants to prokaryotes and archaebacteria. They are obligate intracellular parasites, and as such, subvert many molecular and cellular processes of the host cell to ensure their own replication, amplification, and subsequent spread. This Special Issue addresses the cell biology of viral infections based on a collection of original research articles, communications, opinions, and reviews on various aspects of virus–host cell interactions. Together, these articles not only provide a glance into the latest research on the cell biology of viral infections but also include novel technological developments.

Research & information: general --- Biology, life sciences --- ectoderm --- mesoderm --- human development --- embryogenesis --- interferon response --- interferon-induced genes --- self-organizing map (SOM) data portrayal --- epigenetic signature --- embryoid body --- TGF-β and Wnt/β-catenin pathway --- interferon --- tumor necrosis factor --- STAT --- interferon regulatory factor --- antiviral --- autoimmunity --- inflammation --- hepatitis C virus --- HCV --- erlin-1 --- erlin-2 --- host factor --- endoplasmic reticulum --- RNA replication --- protein production --- virus production --- lipid droplet --- TAP-GFP --- fluorescent TAP platform --- antigen presentation --- MHC I --- immune evasion --- BoHV-1 UL49.5 --- virus --- calcium channels --- calcium pumps --- virus–host interaction --- Ebola virus --- filovirus --- inclusion bodies --- NXF1 --- liquid organelles --- mRNA export --- cancer immunotherapy --- oncolytic virus --- herpes simplex virus --- immune checkpoint inhibitor --- angiogenesis inhibitor --- rabies --- uDISCO --- 3D imaging --- rabies pathogenicity --- astrocyte infection --- metabolism --- apoptosis --- autophagy --- HIV-1 spread --- cell-free infection --- cell–cell transmission --- 3D cultures --- mathematical modeling --- environmental restriction --- CAD --- pyrimidine synthesis --- HEV --- particle production --- viral replication --- virus entry --- hantavirus --- Tula virus --- replication --- factory --- RNA synthesis --- Golgi --- stress granules --- actin cytoskeleton --- nucleocapsid transport --- Arp2/3 complex --- ERAP2 --- ERAP2/Iso3 --- microbial infections --- alternative splicing --- SARS-CoV-2 --- host cell response --- coronavirus --- MERS-CoV --- SARS-CoV --- sialic acid --- Siglec --- antiviral peptide --- enveloped viruses --- membrane phosphatidylserine --- envelope disruption --- membrane damage --- antiviral autophagy --- galectin --- bacterial invasion --- adenovirus --- lysophagy --- ESCRT machinery --- cedar virus --- henipavirus --- fusion protein --- endocytosis --- biological activity --- feline coronavirus --- feline enteric coronavirus --- FECV --- feline infectious peritonitis virus --- FIPV --- feline intestinal organoids --- alphaviruses --- cell death --- mosquito --- tolerance --- ectoderm --- mesoderm --- human development --- embryogenesis --- interferon response --- interferon-induced genes --- self-organizing map (SOM) data portrayal --- epigenetic signature --- embryoid body --- TGF-β and Wnt/β-catenin pathway --- interferon --- tumor necrosis factor --- STAT --- interferon regulatory factor --- antiviral --- autoimmunity --- inflammation --- hepatitis C virus --- HCV --- erlin-1 --- erlin-2 --- host factor --- endoplasmic reticulum --- RNA replication --- protein production --- virus production --- lipid droplet --- TAP-GFP --- fluorescent TAP platform --- antigen presentation --- MHC I --- immune evasion --- BoHV-1 UL49.5 --- virus --- calcium channels --- calcium pumps --- virus–host interaction --- Ebola virus --- filovirus --- inclusion bodies --- NXF1 --- liquid organelles --- mRNA export --- cancer immunotherapy --- oncolytic virus --- herpes simplex virus --- immune checkpoint inhibitor --- angiogenesis inhibitor --- rabies --- uDISCO --- 3D imaging --- rabies pathogenicity --- astrocyte infection --- metabolism --- apoptosis --- autophagy --- HIV-1 spread --- cell-free infection --- cell–cell transmission --- 3D cultures --- mathematical modeling --- environmental restriction --- CAD --- pyrimidine synthesis --- HEV --- particle production --- viral replication --- virus entry --- hantavirus --- Tula virus --- replication --- factory --- RNA synthesis --- Golgi --- stress granules --- actin cytoskeleton --- nucleocapsid transport --- Arp2/3 complex --- ERAP2 --- ERAP2/Iso3 --- microbial infections --- alternative splicing --- SARS-CoV-2 --- host cell response --- coronavirus --- MERS-CoV --- SARS-CoV --- sialic acid --- Siglec --- antiviral peptide --- enveloped viruses --- membrane phosphatidylserine --- envelope disruption --- membrane damage --- antiviral autophagy --- galectin --- bacterial invasion --- adenovirus --- lysophagy --- ESCRT machinery --- cedar virus --- henipavirus --- fusion protein --- endocytosis --- biological activity --- feline coronavirus --- feline enteric coronavirus --- FECV --- feline infectious peritonitis virus --- FIPV --- feline intestinal organoids --- alphaviruses --- cell death --- mosquito --- tolerance

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents.

Zika virus --- nucleoside analogues --- antiviral agents --- NS5 --- prodrugs --- ProTides --- neural stem cells --- RNA-dependent RNA polymerase --- cytomegalovirus --- latent infection --- TALEN --- Surveyor nuclease mutation detection assay --- ie-1 gene --- quantitative real-time PCR --- Epstein–Barr virus --- herpes viruses --- lytic gene expression --- Burkitt lymphoma cells --- clozapine --- antipsychotic drug --- antiviral drug --- enteroviruses --- coxsackievirus B4 --- persistent infection --- fluoxetine --- resistance --- mutations --- herpes B virus --- macacine herpesvirus-1 --- genistein --- flavonoids --- acyclovir --- ganciclovir --- Plantago asiatica --- Clerodendrum trichotomum --- RSV --- therapeutic effects --- acteoside --- human antimicrobial peptides --- antiviral strategies --- defensins --- cathelicidins --- hepcidins --- transferrins --- influenza A virus --- brevilin A --- antiviral --- sesquiterpene lactone --- replication --- PRRSV --- polyethylenimine --- PEI --- virion internalization --- endocytosis --- HIV --- pediatrics --- Ethiopia --- pre-treatment drug resistance --- combination antiretroviral therapy (cART) --- dried plasma spots --- dried blood spots --- sphingolipids --- glycosphingolipids --- viruses --- lipid biosynthesis --- flavivirus --- Japanese encephalitis virus --- furin inhibitor --- precursor membrane protein --- measles virus --- central nervous system --- tropism --- treatments --- porcine reproductive and respiratory syndrome virus --- ginsenoside Rg1 --- antiviral activity --- pro-inflammatory factor --- NF-κB signaling pathway --- acute/latent infection --- congenital infection --- antiviral agent --- therapeutic strategies --- nucleic acid-based therapeutic approach --- HCMV vaccine --- adoptive cell therapy --- Rev response element --- chemical footprinting --- SHAPE --- drug discovery --- branched peptides --- herpesvirus --- immediate-early --- IE1 --- IE2 --- ribozyme --- RNA interference --- CRISPR/Cas --- small molecule --- orthohantavirus --- phenyl-benzotriazoles --- C-FRA --- Porcine circovirus type 2 --- epigallocatechin gallate --- heparan sulfate --- antiviral effect --- virus attachment --- microvirin --- lectin --- human immunodeficiency virus --- hepatitis C virus --- antiviral inhibitor --- non-immunogenic --- viral entry --- protein drugs --- LUMS1 --- oleanane-type derivatives --- influenza A virus (IAV) --- virus entry inhibitors --- hemagglutinin (HA) --- n/a --- Epstein-Barr virus

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents.

Research & information: general --- Biology, life sciences --- Zika virus --- nucleoside analogues --- antiviral agents --- NS5 --- prodrugs --- ProTides --- neural stem cells --- RNA-dependent RNA polymerase --- cytomegalovirus --- latent infection --- TALEN --- Surveyor nuclease mutation detection assay --- ie-1 gene --- quantitative real-time PCR --- Epstein-Barr virus --- herpes viruses --- lytic gene expression --- Burkitt lymphoma cells --- clozapine --- antipsychotic drug --- antiviral drug --- enteroviruses --- coxsackievirus B4 --- persistent infection --- fluoxetine --- resistance --- mutations --- herpes B virus --- macacine herpesvirus-1 --- genistein --- flavonoids --- acyclovir --- ganciclovir --- Plantago asiatica --- Clerodendrum trichotomum --- RSV --- therapeutic effects --- acteoside --- human antimicrobial peptides --- antiviral strategies --- defensins --- cathelicidins --- hepcidins --- transferrins --- influenza A virus --- brevilin A --- antiviral --- sesquiterpene lactone --- replication --- PRRSV --- polyethylenimine --- PEI --- virion internalization --- endocytosis --- HIV --- pediatrics --- Ethiopia --- pre-treatment drug resistance --- combination antiretroviral therapy (cART) --- dried plasma spots --- dried blood spots --- sphingolipids --- glycosphingolipids --- viruses --- lipid biosynthesis --- flavivirus --- Japanese encephalitis virus --- furin inhibitor --- precursor membrane protein --- measles virus --- central nervous system --- tropism --- treatments --- porcine reproductive and respiratory syndrome virus --- ginsenoside Rg1 --- antiviral activity --- pro-inflammatory factor --- NF-κB signaling pathway --- acute/latent infection --- congenital infection --- antiviral agent --- therapeutic strategies --- nucleic acid-based therapeutic approach --- HCMV vaccine --- adoptive cell therapy --- Rev response element --- chemical footprinting --- SHAPE --- drug discovery --- branched peptides --- herpesvirus --- immediate-early --- IE1 --- IE2 --- ribozyme --- RNA interference --- CRISPR/Cas --- small molecule --- orthohantavirus --- phenyl-benzotriazoles --- C-FRA --- Porcine circovirus type 2 --- epigallocatechin gallate --- heparan sulfate --- antiviral effect --- virus attachment --- microvirin --- lectin --- human immunodeficiency virus --- hepatitis C virus --- antiviral inhibitor --- non-immunogenic --- viral entry --- protein drugs --- LUMS1 --- oleanane-type derivatives --- influenza A virus (IAV) --- virus entry inhibitors --- hemagglutinin (HA) --- Zika virus --- nucleoside analogues --- antiviral agents --- NS5 --- prodrugs --- ProTides --- neural stem cells --- RNA-dependent RNA polymerase --- cytomegalovirus --- latent infection --- TALEN --- Surveyor nuclease mutation detection assay --- ie-1 gene --- quantitative real-time PCR --- Epstein-Barr virus --- herpes viruses --- lytic gene expression --- Burkitt lymphoma cells --- clozapine --- antipsychotic drug --- antiviral drug --- enteroviruses --- coxsackievirus B4 --- persistent infection --- fluoxetine --- resistance --- mutations --- herpes B virus --- macacine herpesvirus-1 --- genistein --- flavonoids --- acyclovir --- ganciclovir --- Plantago asiatica --- Clerodendrum trichotomum --- RSV --- therapeutic effects --- acteoside --- human antimicrobial peptides --- antiviral strategies --- defensins --- cathelicidins --- hepcidins --- transferrins --- influenza A virus --- brevilin A --- antiviral --- sesquiterpene lactone --- replication --- PRRSV --- polyethylenimine --- PEI --- virion internalization --- endocytosis --- HIV --- pediatrics --- Ethiopia --- pre-treatment drug resistance --- combination antiretroviral therapy (cART) --- dried plasma spots --- dried blood spots --- sphingolipids --- glycosphingolipids --- viruses --- lipid biosynthesis --- flavivirus --- Japanese encephalitis virus --- furin inhibitor --- precursor membrane protein --- measles virus --- central nervous system --- tropism --- treatments --- porcine reproductive and respiratory syndrome virus --- ginsenoside Rg1 --- antiviral activity --- pro-inflammatory factor --- NF-κB signaling pathway --- acute/latent infection --- congenital infection --- antiviral agent --- therapeutic strategies --- nucleic acid-based therapeutic approach --- HCMV vaccine --- adoptive cell therapy --- Rev response element --- chemical footprinting --- SHAPE --- drug discovery --- branched peptides --- herpesvirus --- immediate-early --- IE1 --- IE2 --- ribozyme --- RNA interference --- CRISPR/Cas --- small molecule --- orthohantavirus --- phenyl-benzotriazoles --- C-FRA --- Porcine circovirus type 2 --- epigallocatechin gallate --- heparan sulfate --- antiviral effect --- virus attachment --- microvirin --- lectin --- human immunodeficiency virus --- hepatitis C virus --- antiviral inhibitor --- non-immunogenic --- viral entry --- protein drugs --- LUMS1 --- oleanane-type derivatives --- influenza A virus (IAV) --- virus entry inhibitors --- hemagglutinin (HA)